Literature DB >> 16896676

[Prognostic factors in ductal carcinoma in situ].

A Lebeau1.   

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous disease that progresses to invasive cancer in 30-50% of the patients. Its natural history is poorly defined so that we are unable to identify cases of DCIS that do not progress to invasive carcinoma during an individual's lifetime. However, pathologic features of DCIS are nowadays the basis for the estimation of the prognosis and planning of therapy. Exclusion of microinvasion, characterization of nuclear grade, architecture, size and distribution of the DCIS, presence or absence of comedonecrosis as well as the assessment of surgical margins are relevant factors for local treatment. The determination of steroid hormone receptor status is indicated in patients considering tamoxifen therapy after breast conservation. It is advisable to evaluate the features according to internationally accepted guidelines with proven prognostic relevance and reproducibility. Nevertheless, better prognostic factors are needed to adapt the management of this increasingly diagnosed disease to the individual patient.

Entities:  

Mesh:

Year:  2006        PMID: 16896676     DOI: 10.1007/s00292-006-0853-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  64 in total

1.  Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status.

Authors:  Melvin J Silverstein; Claire Buchanan
Journal:  Breast       Date:  2003-12       Impact factor: 4.380

Review 2.  Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee.

Authors: 
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

3.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization.

Authors:  C O Bellamy; C McDonald; D M Salter; U Chetty; T J Anderson
Journal:  Hum Pathol       Date:  1993-01       Impact factor: 3.466

5.  Long-term follow-up of in situ carcinoma of the breast.

Authors:  V Eusebi; E Feudale; M P Foschini; A Micheli; A Conti; C Riva; S Di Palma; F Rilke
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

6.  Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.

Authors:  R F Padmore; B Fowble; J Hoffman; C Rosser; A Hanlon; A S Patchefsky
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

7.  Duct carcinoma in situ. Pathology and treatment.

Authors:  M D Lagios
Journal:  Surg Clin North Am       Date:  1990-08       Impact factor: 2.741

8.  EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Angela Unholzer; Gudrun Amann; Michaela Kronawitter; Ingo Bauerfeind; Andrea Sendelhofert; Anette Iff; Udo Löhrs
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

9.  Molecular markers in ductal carcinoma in situ of the breast.

Authors:  Dale Porter; Jaana Lahti-Domenici; Aparna Keshaviah; Young Kyung Bae; Pedram Argani; Jeffrey Marks; Andrea Richardson; Amiel Cooper; Robert Strausberg; Gregory J Riggins; Stuart Schnitt; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

Review 10.  Overview of the biology and management of ductal carcinoma in situ of the breast.

Authors:  E R Frykberg; K I Bland
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

View more
  5 in total

1.  [The role of the pathologist in mammography screening].

Authors:  U Bettendorf; A Fisseler-Eckhoff
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

2.  Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey.

Authors:  M T van Mackelenbergh; C M Lindner; T Heilmann; I Alkatout; M Elessawy; C Mundhenke; N Maass; C Schem
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-01       Impact factor: 2.915

3.  DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

Authors:  R Souchon; M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-01       Impact factor: 3.621

4.  Informed shared decision-making supported by decision coaches for women with ductal carcinoma in situ: study protocol for a cluster randomized controlled trial.

Authors:  Birte Berger-Höger; Katrin Liethmann; Ingrid Mühlhauser; Burkhard Haastert; Anke Steckelberg
Journal:  Trials       Date:  2015-10-12       Impact factor: 2.279

5.  Implementation of shared decision-making in oncology: development and pilot study of a nurse-led decision-coaching programme for women with ductal carcinoma in situ.

Authors:  Birte Berger-Höger; Katrin Liethmann; Ingrid Mühlhauser; Anke Steckelberg
Journal:  BMC Med Inform Decis Mak       Date:  2017-12-06       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.